Gaston Capital Partners

Gaston Capital Partners, LLC is a private equity firm based in Gastonia, North Carolina, founded in 2007. With over thirty-five years of experience in managing investment portfolios and collaborating with small businesses, the firm focuses on investments in various sectors, including industrial, healthcare, manufacturing, and financial services. Its portfolio features specialty pharmaceuticals, medical devices such as cardio-assist and orthopedic replacements, as well as products related to print rolls and industrial turbines. Gaston Capital Partners primarily targets opportunities within the eastern United States.

4 past transactions

Mobility Designed

Venture Round in 2018
Mobility Designed is a manufacturer and distributor of mobility devices for people with mobility challenges. It designs crutches that help users eliminate the pain and discomfort of traditional mobility devices, and increase the likelihood of non-weight bearing compliance that enables users to deal with restricted mobility in a pain-free manner. Mobility Designed was established in 2014 and is headquartered in Kansas City, Missouri.

UltraForce Staffing Services

Acquisition in 2017
Ultra Force Staffing Services is a professional staffing and work-to-hire service with locations in Gastonia, Lincolnton, Shelby, Statesville and Hickory NC. The Company places skilled and semi-skilled labor in manufacturing, assembly and clerical positions to a wide range of industries in Western North Carolina.

Intezyne

Series A in 2017
Intezyne Technologies, Inc. is a clinical-stage biotechnology company based in Tampa, Florida, that focuses on drug development for cancer treatment. The company utilizes its IVECT Method, a nanotechnology platform designed to enhance the anti-tumor activity of chemotherapeutics by delivering them directly within tumors. Intezyne's product portfolio includes several candidates, such as IT-139, which targets the GRP78 pathway, IT-141, a micelle nanoparticle aimed at metastatic solid tumors, and IT-147, which encapsulates epothilone-D in the IVECT micelle. The company is also engaged in developing multi-modal oncology compounds that integrate tissue, cellular, and molecular targeting with tumor-specific release mechanisms. Furthermore, Intezyne conducts active preclinical research programs focused on delivering DNA, siRNA, and other molecularly targeted drugs. Founded in 2004, Intezyne continues to advance its innovative approaches to improve cancer therapies.
First Capital Surety & Trust Co. is an independent state-chartered trust company with its charter situs being South Dakota.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.